Forza Wealth Management LLC Sells 260 Shares of Novo Nordisk A/S (NYSE:NVO)

Forza Wealth Management LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 2.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,666 shares of the company’s stock after selling 260 shares during the period. Forza Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,090,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S in the 3rd quarter worth $28,000. Abound Wealth Management boosted its stake in Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares during the period. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S in the 3rd quarter worth $42,000. Finally, Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter worth $48,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NVO. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded down $1.85 during trading hours on Monday, hitting $84.41. The company had a trading volume of 5,484,888 shares, compared to its average volume of 7,121,949. The firm has a market cap of $378.79 billion, a PE ratio of 27.32, a PEG ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a one year low of $81.50 and a one year high of $148.15. The firm has a 50-day moving average of $100.35 and a 200 day moving average of $119.04.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.